# EDGAR Filing Document

**Accession Number:** 0001604950
**File Stem:** 0001193125-25-186947
**Filing Date:** 2025-8
**Character Count:** 11777
**Document Hash:** cc27d8d9e20d792121405975c1a92161
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-186947.hdr.sgml**: 20250825

**ACCESSION NUMBER**: 0001193125-25-186947

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250820

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250825

**DATE AS OF CHANGE**: 20250825

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** scPharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001604950
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 465184075
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38293
- **FILM NUMBER:** 251247819

**BUSINESS ADDRESS:**
- **STREET 1:** 25 BURLINGTON MALL ROAD, SUITE 203
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
- **BUSINESS PHONE:** 617-517-0730

**MAIL ADDRESS:**
- **STREET 1:** 25 BURLINGTON MALL ROAD, SUITE 203
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of report (Date of earliest event reported): August 20, 2025

## scPharmaceuticals Inc.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38293** | **46-5184075** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **25 Mall Road, Suite 203**<br> **Burlington, Massachusetts** | **01803** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

(617) 517-0730

#### (Registrant's telephone number, including area code)

#### N/A

#### (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common stock, par value $0.0001 per share | SCPH | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 1.01** | **Entry into a Material Definitive Agreement.**  |

---

On August 20, 2025, scPharmaceuticals Inc. (the "Company") entered into an amendment (the "Amendment") to that certain Supply Agreement, dated August 15, 2020, by and between the Company and West Pharmaceutical Services, Inc. ("West"), pursuant to which the Company agreed to purchase the SmartDose® drug delivery system developed by West (the "Agreement").

The Amendment provides for, among other things: (i) that the term of the Agreement will continue in effect until December 31, 2027 and does not automatically extend or automatically renew and (ii) upon election of termination of the Agreement by either party, that the Company will be responsible for payment to West for any costs incurred and purchase orders accepted through the date of termination of the Agreement.

The foregoing description of the Amendment is a summary, and is qualified in its entirety by reference to such document, which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| 10.1\* | [Amendment 1 to the Supply Agreement, dated August 20, 2025, by and between West Pharmaceutical Services, Inc. and the Registrant](d931746dex101.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

\* Portions of this exhibit (indicated by asterisks) have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv).

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SCPHARMACEUTICALS INC.** | **SCPHARMACEUTICALS INC.** |
| Date: August 25, 2025 | By: | /s/ John H. Tucker |
|  | Name: | John H. Tucker |
|  | Title: | President and Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1** 

[\*\*\*] Certain information in this document has been excluded pursuant to Regulation S-K, Item

(601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the

Registrant treats as private or confidential.

**AMENDMENT 1 to Supply Agreement** 

THIS AMENDMENT 1 ("Amendment") to the Supply Agreement dated August 15, 2020 (the "Agreement"), as supplemented with the Side Letter to Supply Agreement dated August 15, 2020 (the "Side Letter") between West Pharmaceutical Services, Inc. ("West") and scPharmaceuticals Inc. ("Customer") is effective as of August 16, 2025 ("Amendment Effective Date").

**RECITALS** 

West and Customer entered into the Agreement to which, among other things, West is to supply Customer Products, defined in the Agreement as on-body drug delivery systems based on West SmartDose technology, cartridge, and piston.

West sent a Non-Renewal of Supply Agreement and Exclusivity Agreement to Customer on October 19, 2024, thereby terminating the Agreement on August 15, 2025.

West and Customer desire and are willing to amend the Agreement and Side Letter to revise particular responsibilities and obligations herein; in particular to extend the Agreement and Side Letter to terminate on December 31, 2027.

**NOW, THEREFORE**, in consideration of the mutual promises, covenants, conditions, and provisions contained or referenced herein, West and Customer have reviewed and accepted all references material and any appendices, exhibits, or other attachments hereto and agree to be bound by the terms and conditions set forth in the Agreement as modified herein as follows:

**1.** **DEFINITIONS** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1. <u>Capitalized Terms</u>. Each capitalized term not defined herein shall have the meaning ascribed to it in the
Agreement. In the event of a conflict between the capitalized terms defined and set forth in this Amendment and the defined terms of the Agreement, the definitions set forth in this Amendment shall control.

**2.** **AMENDMENTS TO AGREEMENT** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1. <u>Section</u> <u>3 Term</u>. Section 3 is hereby deleted in its entirety and replaced with
the following:

"<u>Term</u>. This Agreement shall become effective as of the Effective Date, and unless sooner terminated in accordance with the terms herein, this Agreement and related Side Letter dated August 15, 2020 shall remain in effect through will commence on the Effective Date and, unless terminated earlier as provided herein, will continue in effect until December 31, 2027 and does not automatically extend or automatically renew. Six months prior to the expiration of the Term the parties agree to negotiate in good faith new mutually acceptable terms for extension or renewal of the Agreement."

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2. <u>Section</u> <u>15.a Indemnification</u>. Section 15.a of the Agreement is hereby amended by
deleting it in its entirety and replacing it with follows:

[\*\*\*]

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3. Section 18. Price and Price Adjustments. is deleted in its entirety and replaced with the following:

[\*\*\*]

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4. <u>Section</u> <u>24. Default and Termination</u>. New section 24.c is added in its entirety with
the following:

"Upon termination of this Agreement by either party, Customer shall be responsible for payment to West for costs incurred by West through the date of termination, including raw material costs incurred by West for Products for Customer per this Agreement; and any and all accepted Purchase Orders by Customer to West per this Agreement."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <u>Exhibit A. Pricing Exhibit</u>. Exhibit A of the Agreement is hereby amended by deleting it in its entirety
and replacing it with the following:

**EXHIBIT A** 

**PRICING EXHIBIT** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Product</u>: On-body drug delivery system based on West SmartDose
technology, cartridge and piston.

---

| | |
|:---|:---|
| Part Number | Description |
| 19559012 | SMARTDOSE GEN II DEVICE |
| 19558583 | DS PISTON 10ML FR2 D21-7HW RUV 190 |
| 19550709 | CARTRIDGE TUB ASSEMBLY 10ML 30 HOLE RU |

---

[\*\*\*]

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] |
| [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] |
| [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] |
| [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] |
| [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] |
| [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] | [\*\*\*] |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 <u>Exhibit B. Commercial Capacity</u> [\*\*\*]. Section 1.a. Capital Investment is hereby deleted in its
entirety.

------

**3. <u>Miscellaneous</u>**. The Agreement is amended only to the extent necessary to give full effect to this Amendment; the Agreement shall, subject to the foregoing, remain in full force and effect. Terms not otherwise defined herein shall have the same meaning as defined in the Agreement. If there is any inconsistency between the terms of the Agreement and this Amendment, the terms of the latter shall prevail. This Amendment may be executed in any number of counterparts, each of which shall be an original but together shall constitute a single Amendment.

IN WITNESS WHEREOF, and intending to be legally bound, the parties have caused their duly authorized officers to execute this Amendment effective as of the date set forth below.

---

| | |
|:---|:---|
| **scPharmaceuticals Inc.** | **West Pharmaceutical Services, Inc.** |
| /s/ John Tucker | /s/ Aileen Kinsella |
| Name: John Tucker | Name: Aileen Kinsella |
| Title: CEO | Title: Head of Commercial, Proprietary |
| Date: August 20, 2025 | Date: August 20, 2025 |

---